Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 9.12
(-0.44%)
CNY 9.12
(-0.44%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.62 Billion CNY | 14.75% |
| 2022 | 1.41 Billion CNY | 41.54% |
| 2021 | 1 Billion CNY | 126.43% |
| 2020 | 442.38 Million CNY | -37.09% |
| 2019 | 703.23 Million CNY | 3.94% |
| 2018 | 676.58 Million CNY | 56.39% |
| 2017 | 432.63 Million CNY | 99.37% |
| 2016 | 217 Million CNY | -4.91% |
| 2015 | 228.2 Million CNY | 43.52% |
| 2014 | 159 Million CNY | 20.37% |
| 2013 | 132.09 Million CNY | 26.11% |
| 2012 | 104.74 Million CNY | 25.44% |
| 2011 | 83.49 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 1.27 Billion CNY | -21.0% |
| 2024 Q1 | 1.58 Billion CNY | -2.86% |
| 2024 Q2 | 1.62 Billion CNY | 2.51% |
| 2023 Q3 | 1.63 Billion CNY | -2.88% |
| 2023 Q4 | 1.62 Billion CNY | -0.33% |
| 2023 Q1 | 1.51 Billion CNY | 6.95% |
| 2023 FY | 1.62 Billion CNY | 14.75% |
| 2023 Q2 | 1.68 Billion CNY | 10.84% |
| 2022 Q4 | 1.41 Billion CNY | -1.16% |
| 2022 Q3 | 1.43 Billion CNY | 1.15% |
| 2022 Q2 | 1.41 Billion CNY | 3.16% |
| 2022 FY | 1.41 Billion CNY | 41.54% |
| 2022 Q1 | 1.37 Billion CNY | 37.22% |
| 2021 Q1 | 592.35 Million CNY | 33.9% |
| 2021 Q3 | 871.95 Million CNY | 43.57% |
| 2021 Q4 | 1 Billion CNY | 14.88% |
| 2021 FY | 1 Billion CNY | 126.43% |
| 2021 Q2 | 607.34 Million CNY | 2.53% |
| 2020 Q1 | 721.02 Million CNY | 2.53% |
| 2020 FY | 442.38 Million CNY | -37.09% |
| 2020 Q4 | 442.38 Million CNY | -8.29% |
| 2020 Q3 | 482.36 Million CNY | -10.86% |
| 2020 Q2 | 541.13 Million CNY | -24.95% |
| 2019 Q2 | 906 Million CNY | -0.57% |
| 2019 Q1 | 911.19 Million CNY | 34.67% |
| 2019 FY | 703.23 Million CNY | 3.94% |
| 2019 Q4 | 703.23 Million CNY | -18.0% |
| 2019 Q3 | 857.64 Million CNY | -5.34% |
| 2018 Q3 | 586.63 Million CNY | -7.36% |
| 2018 Q2 | 633.27 Million CNY | 26.94% |
| 2018 Q1 | 498.86 Million CNY | 15.31% |
| 2018 FY | 676.58 Million CNY | 56.39% |
| 2018 Q4 | 676.58 Million CNY | 15.33% |
| 2017 Q3 | 412.88 Million CNY | 3.48% |
| 2017 Q4 | 432.63 Million CNY | 4.78% |
| 2017 Q2 | 399 Million CNY | 34.34% |
| 2017 Q1 | 297 Million CNY | 36.87% |
| 2017 FY | 432.63 Million CNY | 99.37% |
| 2016 Q2 | 161.2 Million CNY | -9.03% |
| 2016 Q4 | 217 Million CNY | 65.4% |
| 2016 Q3 | 131.2 Million CNY | -18.61% |
| 2016 Q1 | 177.2 Million CNY | -22.35% |
| 2016 FY | 217 Million CNY | -4.91% |
| 2015 Q3 | 213 Million CNY | -4.04% |
| 2015 FY | 228.2 Million CNY | 43.52% |
| 2015 Q4 | 228.2 Million CNY | 7.14% |
| 2015 Q1 | 208.43 Million CNY | 31.09% |
| 2015 Q2 | 221.97 Million CNY | 6.5% |
| 2014 Q4 | 159 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | 159 Million CNY | 20.37% |
| 2013 FY | 132.09 Million CNY | 26.11% |
| 2012 FY | 104.74 Million CNY | 25.44% |
| 2011 FY | 83.49 Million CNY | 0.0% |